ACTRN12616000374460已完成1 期
A single dose, randomized, blinded, two treatment, three period, three sequence, partial replicate, reference scaled bioequivalence study of a test formulation of bexarotene capsule in a 3 way crossover comparison against the innovator bexarotene capsule conducted under fed conditions in healthy male volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Healthy males
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 19 and 30 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
- •Concomitant drug therapy of any kind
- •Sensitivity to bexarotene or any other similar class of medicines, or the excipients of bexarotene
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
撤回
1 期
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting condition in healthy male and female volunteers.Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.Neurological - Multiple sclerosisACTRN12621000775819Zenith Technology Corporation Limited39
撤回
1 期
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fed conditions in healthy male and female volunteers.Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.Neurological - Multiple sclerosisACTRN12621000887875Zenith Technology Corporation Limited39
已完成
1 期
Comparative assessment of the absorption of a generic formulation of (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets against the innovator (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets conducted under fasting conditions in healthy male and female volunteers(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid is used for the treatment of management of demonstrated thyroid hormone deficiency.Metabolic and Endocrine - Thyroid diseaseACTRN12620000191998Zenith Technology Corporation Limited25
尚未招募
不适用
bioequivalence study of Abacavir / Dolutegravir / Lamivudine (60 mg / 5 mg / 30 mg) Dispersible Tablets in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.CTRI/2021/04/033145Mylan Laboratories Limited
已完成
不适用
Single dose, randomization blinded, two period, two sequence, oral bioequivalence study of Abacavir / Dolutegravir / Lamivudine (60 mg / 5 mg / 30 mg) Dispersible Tablets in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.CTRI/2021/04/032730Mylan Laboratories Limited36